Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamm… Read more
Market Cap & Net Worth: Hypera SA (HYPMY)
Hypera SA (PINK:HYPMY) has a market capitalization of $2.27 Billion ($2.27 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #7080 globally and #3837 in its home market, demonstrating a 2.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hypera SA's stock price $3.59 by its total outstanding shares 632953512 (632.95 Million).
Hypera SA Market Cap History: 2015 to 2025
Hypera SA's market capitalization history from 2015 to 2025. Data shows growth from $2.48 Billion to $2.27 Billion (1.71% CAGR).
Hypera SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hypera SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
Hypera SA's market cap is 0.27 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.52x
Hypera SA's market cap is 1.52 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.48 Billion | $2.96 Billion | $559.87 Million | 0.84x | 4.43x |
| 2016 | $3.69 Billion | $3.29 Billion | $1.18 Billion | 1.12x | 3.13x |
| 2017 | $5.34 Billion | $3.64 Billion | $964.94 Million | 1.47x | 5.54x |
| 2018 | $4.06 Billion | $3.72 Billion | $1.13 Billion | 1.09x | 3.59x |
| 2019 | $4.78 Billion | $3.29 Billion | $1.16 Billion | 1.45x | 4.11x |
| 2020 | $3.68 Billion | $4.09 Billion | $1.30 Billion | 0.90x | 2.84x |
| 2021 | $2.94 Billion | $5.94 Billion | $1.33 Billion | 0.50x | 2.21x |
| 2022 | $5.10 Billion | $7.55 Billion | $1.70 Billion | 0.68x | 3.00x |
| 2023 | $4.52 Billion | $7.91 Billion | $1.65 Billion | 0.57x | 2.74x |
| 2024 | $2.03 Billion | $7.44 Billion | $1.34 Billion | 0.27x | 1.52x |
Competitor Companies of HYPMY by Market Capitalization
Companies near Hypera SA in the global market cap rankings as of March 18, 2026.
Key companies related to Hypera SA by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hypera SA Historical Marketcap From 2015 to 2025
Between 2015 and today, Hypera SA's market cap moved from $2.48 Billion to $ 2.27 Billion, with a yearly change of 1.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.27 Billion | +11.84% |
| 2024 | $2.03 Billion | -55.07% |
| 2023 | $4.52 Billion | -11.29% |
| 2022 | $5.10 Billion | +73.41% |
| 2021 | $2.94 Billion | -20.16% |
| 2020 | $3.68 Billion | -22.96% |
| 2019 | $4.78 Billion | +17.79% |
| 2018 | $4.06 Billion | -24.05% |
| 2017 | $5.34 Billion | +44.98% |
| 2016 | $3.69 Billion | +48.67% |
| 2015 | $2.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hypera SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.27 Billion USD |
| MoneyControl | $2.27 Billion USD |
| MarketWatch | $2.27 Billion USD |
| marketcap.company | $2.27 Billion USD |
| Reuters | $2.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.